SuperworthGuardant Health, Inc. GH
Medical - Diagnostics & Research, Healthcare
$168.33
−1.38%
- Market cap
- $22.6B
- PE
- —
- Forward PE
- Price to sales
- 19.1×
- EV/EBIT
- —
- Revenue, 12 months
- $1.2B
- +43% on a year ago
- Net margin
- −38.3%
- Free cash flow yield
- —
Guardant Health trades at 19.1× sales. Its trailing earnings are negative, so it has no PE. Revenue was $1.2B over the last twelve months, up 43% on a year earlier with a −38% net margin.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $155.1M | $168.5M | $177.2M | $191.5M | $201.8M+30% | $203.5M+21% | $232.1M+31% | $265.2M+39% | $281.3M+39% | $301.7M+48% | $335M+44% | |
| Cost of revenue | $62.5M | $65.3M | $72.4M | $74.5M | $77.6M+24% | $74.7M+14% | $81.2M+12% | $93.6M+26% | $99.5M+28% | $104.9M+40% | $115.9M+43% |
| Gross profit | $92.5M | $103.2M | $104.8M | $117M | $124.2M+34% | $128.7M+25% | $150.9M+44% | $171.6M+47% | $181.8M+46% | $196.7M+53% | $219M+45% |
| R&D | $89.9M | $83.8M | $83.1M | $87.3M | $93.5M+4% | $88.5M+6% | $87.4M+5% | $90M+3% | $98.3M+5% | $91M+3% | $96.5M+10% |
| SG&A | $116.8M | $119.1M | $122.3M | $147M | $156.6M+34% | $151.3M+27% | $169.8M+39% | $180.6M+23% | $204.3M+30% | $227.1M+50% | $251.6M+48% |
| −$197.5M | −$99.7M | −$100.6M | −$117.3M | −$126M−36% | −$111M+11% | −$106.4M+6% | −$99M−16% | −$120.8M−4% | −$121.3M+9% | −$129.1M+21% | |
| Interest expense | $645K | $645K | $645K | $646K | $645K+0% | $791K+23% | $983K+52% | $943K+46% | $1.2M+83% | $1.3M+70% | $1.3M+37% |
| Pre-tax income | −$187.6M | −$114.6M | −$102.5M | −$107.7M | −$110.3M−41% | −$94.9M−17% | −$99.9M−3% | −$92.6M−14% | −$130.2M+18% | −$111.7M+18% | −$120M+20% |
| −$541K | $405K | $133K | $30K | $716K | $290K−28% | $38K−71% | $136K+353% | −$1.7M | $372K+28% | $185K+387% | |
| Net income | −$187M | −$115M | −$102.6M | −$107.8M | −$111M−41% | −$95.2M−17% | −$99.9M−3% | −$92.7M−14% | −$128.5M+16% | −$112.1M+18% | −$120.1M+20% |
| −$1.58 | −$0.94 | −$0.84 | −$0.88 | −$0.90−43% | −$0.77−18% | −$0.80−5% | −$0.74−16% | −$1.00+11% | −$0.85+10% | −$0.90+13% | |
| 118.5M | 121.7M | 122.4M | 123.1M | 123.8M+4% | 123.9M+2% | 124.1M+1% | 124.8M+1% | 128.7M+4% | 131.3M+6% | 132.9M+7% |
From each company's 10-Q and 10-K filings. Fiscal years are four fiscal quarters added up; balance sheet lines are as of the period's end. Growth is on the same period a year earlier.
Estimates
Next earnings report: .
Analyst consensus for the next eight quarters, with the range from the lowest to the highest estimate, is part of Superworth Pro.
Peers
Companies in Medical - Diagnostics & Research within ten times Guardant Health's size, closest in size first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| GHGuardant Health, Inc. | $22.6B | — | — | 19.1× | +43% | −38.3% | |
| DGXQuest Diagnostics Incorporated | $25.1B | 24.1× | 19.1× | 2.2× | +10% | 9.2% | |
| LHLabcorp Holdings Inc. | $25.3B | 25.8× | 21.9× | 1.8× | +6% | 7.0% | |
| MTDMettler-Toledo International Inc. | $30.7B | 34.5× | 36.5× | 7.4× | +7% | 21.9% | |
| IDXXIDEXX Laboratories, Inc. | $39.9B | 35.6× | 54.8× | 8.8× | +13% | 25.0% | |
| ILMNIllumina, Inc. | $40.4B | 49.9× | 50.6× | 9.0× | +5% | 18.4% | |
| IQVIQVIA Holdings Inc. | $42.5B | 32.0× | 35.0× | 2.5× | +8% | 8.1% | |
| WATWaters Corporation | $42.8B | 109× | 29.3× | 9.2× | +52% | 3.6% | |
| AAgilent Technologies, Inc. | $47.7B | 33.3× | 32.4× | 6.5× | +9% | 19.5% | |
| DHRDanaher Corporation | $153.6B | 38.8× | 36.4× | 6.1× | +5% | 15.9% | |
| Peer median | $40.4B | 34.5× | 35.0× | 6.5× | +8% | 15.9% |
About
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .